FGF2 and myocardial infarction: We believe that the present study substantiates the anti-fibrotic influence of LMW-FGF-2 on human cardiac myofibroblasts and demonstrates a proof-of-concept for using LMW-FGF-2 to specifically target ECM dysregulation in the post-MI human heart.